Macrolides: From in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases

European Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2012, Pages 479-503

  Zarogoulidis, P ^a   Papanas, N ^c   Kioumis, I ^a   Chatzaki, E ^c   Maltezos, E ^b   Zarogoulidis, K ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Antibiotics; Immunomodulation; Inflammation; Macrolides

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CLARITHROMYCIN; CORTICOSTEROID; DIRITHROMYCIN; ERYTHROMYCIN; ERYTHROMYCIN DERIVATIVE; GEMIFLOXACIN; IMMUNOMODULATING AGENT; INTERLEUKIN 4; INTERLEUKIN 8; LEVOFLOXACIN; MACROLIDE; MLD 987; MONTELUKAST; MOXIFLOXACIN; OLCOROLIMUS; OSELTAMIVIR; OXECLOSPORIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAPAMYCIN; ROKITAMYCIN; ROXITHROMYCIN; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; THEOPHYLLINE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ASTHMA; BACTERIAL INFECTION; BRONCHIECTASIS; BRONCHIOLITIS; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CARDIOTOXICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONCENTRATION RESPONSE; CYSTIC FIBROSIS; CYTOKINE RELEASE; DISEASE EXACERBATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME ACTIVATION; GASTROINTESTINAL SYMPTOM; HEARING IMPAIRMENT; HUMAN; IC 50; IMMUNOMODULATION; IN VITRO STUDY; INFLUENZA A (H1N1); LIVER TOXICITY; MYCOPLASMA PNEUMONIA; NEUTROPENIA; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT DISEASE; REVIEW; SEPSIS; SYSTEMIC DISEASE; TOXIC HEPATITIS; UNSPECIFIED SIDE EFFECT; URTICARIA;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYSTIC FIBROSIS; HUMANS; IMMUNOLOGIC FACTORS; LUNG DISEASES, OBSTRUCTIVE; MACROLIDES;

EID: 84863710809     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1161-x     Document Type: Review

References (328)

1. Ōmura S (2002) Macrolide antibiotics: chemistry, biology, and practice, 2nd ed. Academic Press, Boston
2. Yip MJ, Porter JL, Fyfe JA, Lavender CJ, Portaels F, Rhodes M, Kator H, Colorni A, Jenkin GA, Stinear T (2007) Evolution of Mycobacterium ulcerans and other mycolactone-producing mycobacteria from a common Mycobacterium marinum progenitor. J Bacteriol 189:2021-2029. doi:10.1128/JB.01442-06 (Pubitemid 46446165)
3. Käser M, Hauser J, Small P, Pluschke G (2009) Large sequence polymorphisms unveil the phylogenetic relationship of environmental and pathogenic mycobacteria related to Mycobacterium ulcerans. Appl Environ Microbiol 75:5667-5675. doi:10.1128/AEM.00446-09
4. Ungureanu V (2010) Macrolides, lincosamides, streptogramines (MLS): mechanisms of action and resistance. Bacteriol Virusol Parazitol Epidemiol 55:131-138
5. Tenson T, Lovmar M, Ehrenberg M (2003) The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol 330:1005-1014. doi:10.1016/S0022-2836(03)00662- 4 (Pubitemid 36818898)
6. Buret AG (2010) Immuno-modulation and anti-inflammatory benefits of antibiotics: the example of tilmicosin. Can J Vet Res 74:1-10
7. Rubin BK, Henke MO (2004) Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest 125 (2 Suppl):70S-78S. doi:10.1378/chest.125.2-suppl.70S (Pubitemid 38200963)
8. Feola DJ, Garvy BA, Cory TJ, Birket SE, Hoy H, Hayes D Jr, Murphy BS (2010) Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. Antimicrob Agents Chemother 54:2437-2447. doi:10.1128/AAC.01424-09
9. Ribeiro CM, Hurd H, Wu Y, Martino ME, Jones L, Brighton B, Boucher RC, O'Neal WK (2009) Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia. PLoS One 4(6):e5806. doi:10.1371/journal.pone.0005806
10. Shinkai M, López-Boado YS, Rubin BK (2007) Clarithromycin has an immunomodulatory effect on ERK-mediated inflammation induced by Pseudomonas aeruginosa flagellin. J Antimicrob Chemother 59:1096-1101. doi:10.1093/jac/ dkm084 (Pubitemid 47073319)
11. Kurata S, Taguchi H, Sasaki T, Fujioka Y, Kamiya S (2010) Antimicrobial and immunomodulatory effect of clarithromycin on macrolide-resistant Mycoplasma pneumoniae. J Med Microbiol 59:693-701. doi:10.1099/jmm.0.014191-0
12. Nakamura H, Fujishima S, Inoue T, Ohkubo Y, Soejima K, Waki Y, Mori M, Urano T, Sakamaki F, Tasaka S, Ishizaka A, Kanazawa M, Yamaguchi K (1999) Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J 13:1371-1379 (Pubitemid 29357155)
13. Guillot L, Tabary O, Nathan N, Corvol H, Clement A (2011) Macrolides: new therapeutic perspectives in lung diseases. Int J Biochem Cell Biol 43(9):1241-1246. doi:10.1016/j.biocel.2011.05.009
14. Sugawara A, Sueki A, Hirose T, Nagai K, Gouda H, Hirono S, Shima H, Akagawa KS, Omura S, Sunazuka T (2011) Novel 12-membered non-antibiotic macrolides from erythromycin A; EM900 series as novel leads for anti-inflammatory and/or immunomodulatory agents. Bioorg Med Chem Lett 21:3373-3376. doi:10.1016/j.bmcl.2011.04.004
15. Viasus D, Paño-Pardo JR, Cordero E, Campins A, López-Medrano F, Villoslada A, Fariñas MC, Moreno A, Rodríguez-Baño J, Oteo JA, Martínez-Montauti J, Torre-Cisneros J, Segura F, Carratalà J, Novel Influenza A (H1N1) Study Group, Spanish Network for Research in Infectious Diseases (2011) Effect of immune-modulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J Infect 62:193-199. doi:10.1016/j.jinf.2011.01.014
16. Houssen ME, Haron MM, Metwally SS, Ibrahim TM (2011) Effects of immunomodulatory drugs on plasma inflammatory markers in a rabbit model of atherosclerosis. J Physiol Biochem 67:115-120. doi:10.1007/s13105-010-0055-1
17. Kanoh S, Rubin BK (2010) Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 23:590-615. doi:10.1128/CMR.00078-09
18. Leiva M, Ruiz-Bravo A, Moreno E, Jiménez-Valera M (2008) Telithromycin inhibits the production of proinflammatory mediators and the activation of NF-kappaB in in vitro-stimulated murine cells. FEMS Immunol Med Microbiol 53:343-350. doi:10.1111/j.1574-695X.2008.00424.x
19. Baziaka F, Giamarellos-Bourboulis EJ, Raftogiannis M, Adamis T, Tziortzioti V, Sabracos L, Chrisofos M, Koutoukas P, Giamarellou H, Douzinas EE (2008) Immunomodulatory effect of three-day continuous administration of clarithromycin for experimental sepsis due to multidrug-resistant Pseudomonas aeruginosa. J Chemother 20:63-68 (Pubitemid 351428665)
20. Shinkai M, Henke MO, Rubin BK (2008) Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther 117:393-405. doi:10.1016/j.pharmthera.2007.11.001
21. Tauber SC, Nau R (2008) Immunomodulatory properties of antibiotics. Curr Mol Pharmacol 1:68-79. doi:10.1080/08923970701692841
22. Wu L, Zhang W, Tian L, Bao K, Li P, Lin J (2007) Immunomodulatory effects of erythromycin and its derivatives on human T-lymphocyte in vitro. Immunopharmacol Immunotoxicol 29:587-596. doi:10.1080/08923970701692841 (Pubitemid 350261187)
23. Blasi F, Cazzola M, Tarsia P, Aliberti S, Baldessari C, Valenti V (2006) Telithromycin in lower respiratory tract infections. Future Microbiol 1:7-16. doi:10.2217/17460913.1.1.7
24. Niclau DP, Tessier R, Rubinstein I, Nightingale CH (2006) In vivo immunomodulatory profile of telithromycin in a murine pneumococcal infection model. Pharmazie 61:343-347
25. Kohyama T, Takizawa H, Kawasaki S, Akiyama N, Sato M, Ito K (1999) Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. Antimicrob Agents Chemother 43:907-911 (Pubitemid 29165756)
26. Legssyer R, Huaux F, Lebacq J, Delos M, Marbaix E, Lebecque P, Lison D, Scholte BJ, Wallemacq P, Leal T (2006) Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. Respir Res 7:134. doi:10.1186/1465-9921-7-134 (Pubitemid 44774213)
27. Abe S, Nakamura H, Inoue S, Takeda H, Saito H, Kato S, Mukaida N, Matsushima K, Tomoike H (2000) Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am J Respir Cell Mol Biol 22:51-60 (Pubitemid 30342959)
28. Black PN (1997) Anti-inflammatory effects of macrolide antibiotics. Eur Respir J 10:971-972. doi:10.1183/09031936.97.10050971 (Pubitemid 27201795)
29. Swords WE, Rubin BK (2003) Macrolide antibiotics, bacterial populations and inflammatory airway disease. Neth J Med 61:242-248 (Pubitemid 39089409)
30. Blau H, Klein K, Shalit I, Halperin D, Fabian I (2007) Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line. Am J Physiol Lung Cell Mol Physiol 292:L343-L352. doi:10.1152/ajplung.00030.2006 (Pubitemid 46103459)
31. Wales D, Woodhead M (1999) The anti-inflammatory effects of macrolides. Thorax 54(Suppl 2):S58-S62. doi:10.1136/thx.54.2008. S58 (Pubitemid 29341397)
32. Takizawa H, Desaki M, Ohtoshi T, Kawasaki S, Kohyama T, Sato M, Nakajima J, Yanagisawa M, Ito K (1998) Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells. Eur Respir J 12:57-63. doi:10.1183/09031936.98.12010057 (Pubitemid 28325654)
33. Sevilla-Sánchez D, Soy-Muner D, Soler-Porcar N (2010) Usefulness of macrolides as anti-inflammatories in respiratory diseases. Arch Bronconeumol 46:244-254. doi:10.1016/j.arbres.2009.10.008
34. Tamaoki J (2004) The effects of macrolides on inflammatory cells. Chest 125(2 Suppl):41S-50S; quiz 51S. doi: 10.1378/chest.125.2-suppl.41S
35. Leiva M, Ruiz-Bravo A, Jimenez-Valera M (2008) Effects of telithromycin in in vitro and in vivo models of lipopolysaccharide-induced airway inflammation. Chest 134:20-29. doi:10.1378/chest.07-3056 (Pubitemid 352008759)
36. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG (2011) Immunomodulatory effects of macrolide antibiotics - part 1: biological mechanisms. Respiration 81:67-74. doi:10.1159/000320319
37. Kumar V, Harjai K, Chhibber S (2008) Effect of clarithromycin on lung inflammation and alveolar macrophage function in Klebsiella pneumoniae B5055-induced acute lung infection in BALB/c mice. J Chemother 20:609-614
38. Ivetić Tkalcević V, Bosnjak B, Hrvacić B, Bosnar M, Marjanović N, Ferencić Z, Situm K, Culić O, Parnham MJ, Eraković V (2006) Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice. Eur J Pharmacol 539:131-138. doi:10.1016/j.ejphar.2006.03.074 (Pubitemid 44208808)
39. Davidson R, Péloquin L (2002) Anti-inflammatory effects of the macrolides. J Otolaryngol 31(Suppl 1):S38-40
40. Marjanović N, Bosnar M, Michielin F, Willé DR, Anić-Milić T, Culić O, Popović-Grle S, Bogdan M, Parnham MJ, Haber VE (2011) Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro. Pharmacol Res 63:389-397. doi:10.1016/j.phrs.2011.02.001
41. Marot A, Morelle J, Chouinard VA, Jadoul M, Lambert M, Demoulin N (2011) Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature. Acta Clin Belg 66:134-136
42. Giorgi MA, Caroli C, Arazi HC, Di Girolamo G (2011) Pharmacogenomics and adverse drug reactions: the case of statins. Expert Opin Pharmacother 12:1499-1509. doi:10.1517/14656566.2011.563734
43. Gao X, Ray R, Xiao Y, Ishida K, Ray P (2010) Macrolide antibiotics improve chemotactic and phagocytic capacity as well as reduce inflammation in sulfur mustard-exposed monocytes. Pulm Pharmacol Ther 23:97-106. doi:10.1016/j.pupt.2009.10.010
44. Hrvacić B, Bosnjak B, Bosnar M, Ferencić Z, Glojnarić I, Eraković Haber V (2009) Clarithromycin suppresses airway hyper-responsiveness and inflammation in mouse models of asthma. Eur J Pharmacol 616:236-243. doi:10.1016/j.ejphar.2009.06.032
45. Beigelman A, Gunsten S, Mikols CL, Vidavsky I, Cannon CL, Brody SL, Walter MJ (2009) Azithromycin attenuates airway inflammation in a noninfectious mouse model of allergic asthma. Chest 136:498-506. doi:10.1378/chest.08-3056
46. Pinto LA, Camozzato C, Avozani M, Machado DC, Jones MH, Stein RT, Pitrez PM (2004) Effect of clarithromycin on the cell profile of bronchoalveolar lavage fluid in mice with neutrophil-predominant lung disease. Rev Hosp Clin Fac Med Sao Paulo 59:99-103
47. Banerjee D, Honeybourne D, Khair OA (2004) The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial. Treat Respir Med 3(1):59-65 (Pubitemid 38444332)
48. Beuther DA, Martin RJ (2004) Antibiotics in asthma. Curr Allergy Asthma Rep 4:132-138 (Pubitemid 38906754)
49. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M (2002) Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360:978-984 (Pubitemid 35284109)
50. Kunisaki KN, Niewoehner DE (2008) Antibiotic prophylaxis for chronic obstructive pulmonary disease. Resurrecting an old idea. Am J Respir Crit Care Med 178:1098-1099. doi:10.1164/rccm.200808-1315ED
51. Cardinale F, Chironna M, Dumke R, Binetti A, Daleno C, Sallustio A, Valzano A, Esposito S (2011) Macrolide-resistant Mycoplasma pneumoniae in paediatric pneumonia. Eur Respir J 37:1522-1524. doi:10.1183/09031936.00172510
52. Phaff SJ, Tiddens HA, Verbrugh HA, Ott A (2006) Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. J Antimicrob Chemother 57:741-746. doi:10.1093/jac/dkl014
53. Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK (2007) Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J 26:8-12. doi:10.1097/01.inf.0000247109.44249.ac (Pubitemid 46045744)
54. Inoue M, Farrell DJ, Kaneko K (2008) Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years 1-5 (1999-2004). Microb Drug Resist 14:109-117. doi:10.1089/mdr.2008.0806
55. Jacobs E, Dalhoff A, Korfmann G (2009) Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study). Int J Antimicrob Agents 33:52-57. doi:10.1016/j.ijantimicag. 2008.07.017
56. Karlowsky JA, Lagace-Wiens PR, Low DE (2009) Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005. Int J Antimicrob Agents 34:375-379. doi:10.1016/j.ijantimicag.2009.05.008
57. Pihlajamaki M, Kaijalainen T, Huovinen P (2002) Rapid increase in macrolide resistance among penicillin non-susceptible pneumococci in Finland, 1996-2000. J Antimicrob Chemother 49:785-792. doi:10.1093/jac/dkf033 (Pubitemid 34537639)
58. Barkai G, Greenberg D, Givon-Lavi N, Dreifuss E, Vardy D, Dagan R (2005) Community prescribing and resistant Streptococcus pneumoniae. Emerg Infect Dis 11(6):829-837 (Pubitemid 40720842)
59. Bergman M, Huikko S, Huovinen P, Paakkari P, Seppälä H, Finnish Study Group for Antimicrobial Resistance (FiRe Network) (2006) Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 50(11):3646-3650. doi:10.1128/AAC.00234- 06 (Pubitemid 44684876)
60. García-Rey C, Aguilar L, Baquero F, Casal J, Dal-Ré R (2002) Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. J Clin Microbiol 40(1):159-164. doi:10.1128/JCM.40.1.159-164.2002 (Pubitemid 34027619)
61. McGhan LJ, Merchant SN (2003) Erythromycin ototoxicity. Otol Neurotol 24(4):701-702
62. Boucher RC, Van Scott MR, Willumsen N, Stutts MJ (1988) Epithelial injury. Mechanisms and cell biology of airway epithelial injury. Am Rev Respir Dis 138(6 Pt 2):S41-S4
63. Leme CV, Raposo LS, Ruiz MT, Biselli JM, Galbiatti AL, Maniglia JV, Pavarino-Bertelli EC, Goloni-Bertollo EM (2010) GSTM1 and GSTT1 genes analysis in head and neck cancer patients. Rev Assoc Med Bras 56:299-303
64. McGrath-Morrow SA, Stahl JL (2000) G(1) Phase growth arrest and induction of p21(Waf1/Cip1/Sdi1) in IB3-1 cells treated with 4-sodium phenylbutyrate. J Pharmacol Exp Ther 294:941-947 (Pubitemid 30666844)
65. Jiang C, Finkbeiner WE, Widdicombe JH, Fang SL, Wang KX, Nietupski JB, Hehir KM, Cheng SH (1999) Restoration of cyclic adenosine monophosphate- stimulated chloride channel activity in human cystic fibrosis tracheobronchial submucosal gland cells by adenovirus-mediated and cationic lipid-mediated gene transfer. Am J Respir Cell Mol Biol 20:1107-1115 (Pubitemid 129503228)
66. Bergamini G, Cigana C, Sorio C, Della Peruta M, Pompella A, Corti A, Huaux FA, Leal T, Assael BM, Melotti P (2009) Effects of azithromycin on glutathione S-transferases in cystic fibrosis airway cells. Am J Respir Cell Mol Biol 41:199-206. doi:10.1165/rcmb.2008-0013OC
67. Cigana C, Assael BM, Melotti P (2007) Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother 51:975-981. doi:10.1128/AAC.01142-06 (Pubitemid 46355283)
68. Ilowite J, Spiegler P, Kessler H (2009) Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents. Drugs 69:407-419. doi:10.2165/00003495-200969040-00002
69. Owczarek W, Paluchowska E (2008) The macrolide antibiotics in treatment of skin diseases. Pol Merkur Lekarski 25:429-431
70. Southern KW, Barker PM (2004) Azithromycin for cystic fibrosis. Eur Respir J 24(5):834-838. doi:10.1183/09031936.04.00084304 (Pubitemid 39504439)
71. Bornhövd EC, Schuller E, Bieber T, Wollenberg A (2000) Immunosuppressive macrolides and their use in dermatology. Hautarzt 51:646-654
72. Karrow NA, McCay JA, Brown RD, Musgrove DL, Germolec DR, White KL Jr (2001) Evaluation of the immunomodulatory effects of the macrolide antibiotic, clarithromycin, in female B6C3F1 mice: a 28-day oral gavage study. Drug Chem Toxicol 24:19-37. doi:10.1081/DCT-100103083 (Pubitemid 32289921)
73. Langelot M, Cellerin L, Germaud P (2006) Anti-inflammatory effects of macrolides: applications in lung disease. Rev Pneumol Clin 62:215-222 (Pubitemid 44606129)
74. Wu L, Lin JH, Bao K, Li PF, Zhang WG (2009) In vitro effects of erythromycin on RANKL and nuclear factor-kappa B by human TNF-alpha stimulated Jurkat cells. Int Immunopharmacol 9(9):1105-1109. doi:10.1016/j.intimp.2009.05. 008
75. Tone A, Shikata K, Sasaki M, Ohga S, Yozai K, Nishishita S, Usui H, Nagase R, Ogawa D, Okada S, Shikata Y, Wada J, Makino H (2005) Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats. Diabetologia 48(11):2402-2411. doi:10.1007/s00125-005-1945-6 (Pubitemid 41618933)
76. Sanz MJ, Nabah YN, Cerdá-Nicolás M, O'Connor JE, Issekutz AC, Cortijo J, Morcillo EJ (2005) Erythromycin exerts in vivo anti-inflammatory activity downregulating cell adhesion molecule expression. Br J Pharmacol 144(2):190-201. doi:10.1038/sj. bjp.0706021 (Pubitemid 40216117)
77. Yu C, Azuma A, Li Y, Wang C, Abe S, Usuki J, Matsuda K, Kudoh S, Sunazuka T, Omura S (2008) EM703, a new derivative of erythromycin, inhibits transforming growth factor-beta signaling in human lung fibroblasts. Exp Lung Res 34(6):343-354. doi:10.1080/01902140802093238 (Pubitemid 351948465)
78. He Z, Li B, Yu L, Liu Q, Zhong N, Ran P (2008) Suppression of oxidant-induced glutathione synthesis by erythromycin in human bronchial epithelial cells. Respiration 75(2):202-209. doi:10.1159/000111569 (Pubitemid 351363876)
79. Harita S, Kuyama S, Okada T, Tanizaki Y (2008) Effect of long-term and low-dose administration of erythromycin on proliferation of T lymphocytes stimulated with mitogens. J Chemother 20 (5):604-608
80. Hirohata S, Nakanishi K (1995) Suppression of cytokine production of human memory T cells by roxithromycin. Arerugi 44(11):1322-1330 (Pubitemid 26024197)
81. Oyama T, Sakuta T, Matsushita K, Maruyama I, Nagaoka S, Torii M (2000) Effects of roxithromycin on tumor necrosis factor-alpha-induced vascular endothelial growth factor expression in human periodontal ligament cells in culture. J Periodontol 71(10):1546-1553. doi:10.1902/jop.2000.71.10.1546
82. Oyama T, Matsushita K, Sakuta T, Tokuda M, Tatsuyama S, Nagaoka S, Torii M (2007) Roxithromycin inhibits tumor necrosis factor-alpha-induced matrix metalloproteinase-1 expression through regulating mitogen-activated protein kinase phosphorylation and Ets-1 expression. J Periodontal Res 42(1):53-61. doi:10.1111/j.1600-0765.2006.00914.x
83. Kobayashi M, Shimauchi T, Hino R, Tokura Y (2004) Roxithromycin downmodulates Th2 chemokine production by keratinocytes and chemokine receptor expression on Th2 cells: its dual inhibitory effects on the ligands and the receptors. Cell Immunol 228(1):27-33. doi:10.1016/j.cellimm.2004.03.011 (Pubitemid 38760120)
84. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, RogersRM SFC, Coxson HO, Pari PD (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350:2645-2653. doi:10.1056/NEJMoa032158 (Pubitemid 38787999)
85. Gompertz S, O'Brien C, Bayley DL, Hill SL, Stockley RA (2001) Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 17:1112-1119 (Pubitemid 32717466)
86. Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, Postma D, Saetta M (2006) Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir CritCare Med 174:6-14. doi:10.1164/rccm.200510-1659PP (Pubitemid 43955238)
87. Snell N, Newbold P (2008) The clinical utility of biomarkers in asthma and COPD. Curr Opin Pharmacol 8:222-235. doi:10.1016/j.coph.2008.04.001
88. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG (2011) Immunomodulatory effects of macrolide antibiotics - part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration 81:75-87. doi:10.1159/000320320
89. López-Boado YS, Rubin BK (2008) Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr Opin Pharmacol 8:286-291. doi:10.1016/j.coph.2008.01.010
90. Healy DP (2007) Macrolide immunomodulation of chronic respiratory diseases. Curr Infect Dis Rep 9:7-13 (Pubitemid 46242407)
91. Bishai WR (2006) Macrolide immunomodulatory effects and symptom resolution in acute exacerbation of chronic bronchitis and acute maxillary sinusitis: a focus on clarithromycin. Expert Rev Anti Infect Ther 4:405-416. doi:10.1586/14787210.4.3.405 (Pubitemid 43905463)
92. Mazza-Stalder J, Siegrist CA, Janssens JP (2005) Immunization and immuno-modulation for prevention of respiratory tract infections. Rev Med Suisse 1(2645-2646):2649-2651
93. Parnham MJ, Culić O, Eraković V, Munić V, Popović-Grle S, Barisić K, Bosnar M, Brajsa K, Cepelak I, Cuzić S, Glojnarić I, Manojlović Z, Novak-Mircetić R, Oresković K, Pavicić-Beljak V, Radosević S, Sucić M (2005) Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. Eur J Pharmacol 517:132-143 (Pubitemid 40916224)
94. Basyigit I, Yildiz F, Ozkara SK, Yildirim E, Boyaci H, Ilgazli A (2004) The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data. Ann Pharmacother 38:1400-1405. doi:10.1345/aph.1D634 (Pubitemid 39100191)
95. Zhong XN, Bai J, Shi HZ, Wu C, Liang GR, Feng ZB (2003) An experimental study on airway inflammation and remodeling in a rat model of chronic bronchitis and emphysema. Zhonghua Jie He He Hu Xi Za Zhi 26:750-755
96. Gotfried MH (2004) Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 125(2 Suppl):52S-60S; quiz 60S-61S. doi: 10.1378/chest.125.2-suppl.52S
97. Amsden GW (2005) Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions. J Antimicrob Chemother 55:10-21. doi: 10.1093/jac/dkh519 (Pubitemid 40192609)
98. Martinez FJ, Curtis JL, Albert R (2008) Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 3:331-350
99. Nakanishi Y, Kobayashi D, Asano Y, Sakurai T, Kashimura M, Okuyama S, Yoneda Y, Shapiro SD, Takayama K (2009) Clarithromycin prevents smoke-induced emphysema in mice. Am J Respir CritCare Med 179:271-278. doi:10.1164/rccm. 200806-905OC
100. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA (2008) Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 178:1139-1147
101. He Z-Y, Ou L-M, Zhang J-Q, Bai J, Liu G-N, Li M-H, Deng J-M, Mac Nee W, Zhong X-N (2010) Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration 80:445-452. doi:10.1159/000321374
102. Banerjee D, Khair OA, Honeybourne D (2005) The effect of oral clarithromycin on ealth status and sputum bacteriology in stable COPD. Respir Med 99:208-215. doi:10.1016/j.rmed.2004.06.009 (Pubitemid 40104276)
103. Blasi F, Bonardi D, Aliberti S, Tarsia P, Confalonieri M, Amir O, Carone M, Di Marco F, Centanni S, Guffanti E (2010) Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm Pharmacol Ther 23:200-207. doi:10.1016/j.pupt.2009.12.002
104. Léophonte P, Zuck P, Perronne C, Baconnet B (2008) Routine use of extended-release clarithromycin tablets for short-course treatment of acute exacerbations of non-severe COPD. Med Mal Infect 38:471-476. doi:10.1016/j.medmal.2008.06.029
105. Gotfried M, Busman TA, Norris S, Notario GF (2007) Role for 5-day, once-daily extended-release clarithromycin in acute bacterial exacerbation of chronic bronchitis. Curr Med Res Opin 23:459-466. doi:10.1185/030079906X162827 (Pubitemid 46333393)
106. Zervos M, Martinez FJ, Amsden GW, Rothermel CD, Treadway G (2007) Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis. Int J Antimicrob Agents 29:56-61. doi:10.1016/j.ijantimicag.2006.08.043 (Pubitemid 44959787)
107. Gotfried M, Notario G, Spiller J, Palmer R, Busman T (2005) Comparative efficacy of once daily, 5-day short-course therapy with clarithromycin extended-release versus twice daily, 7-day therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis. Curr Med Res Opin 21:245-254. doi:10.1185/030079905X26243 (Pubitemid 40469900)
108. Swanson RN, Lainez-Ventosilla A, De Salvo MC, Dunne MW, Amsden GW (2005) Once-daily azithromycin for 3 days compared with clarithromycin for 10 days for acute exacerbation of chronic bronchitis: a multicenter, double-blind, randomized study. Treat Respir Med 4:31-39 (Pubitemid 40360817)
109. Nalepa P, Dobryniewska M, Busman T, Notario G (2003) Short-course therapy of acute bacterial exacerbation of chronic bronchitis: a double-blind, randomized, multicenter comparison of extended-release versus immediate-release clarithromycin. Curr Med Res Opin 19:411-420. doi:10.1185/030079903125002018 (Pubitemid 36994444)
110. Watz H, Kanniess F, Magnussen H (2007) New pharmacological options in the therapy of COPD. Pneumologie 61(6):365-373 (Pubitemid 47091747)
111. Weiss K, Vanjaka A, Canadian Clarithromycin Study Group on Bronchitis (2002) An open-label, randomized, multicenter, comparative study of the efficacy and safety of 7 days of treatment with clarithromycin extended-release tablets versus clarithromycin immediate-release tablets for the treatment of patients with acute bacterial exacerbation of chronic bronchitis. Clin Ther 24:2105-2122 (Pubitemid 36051534)
112. Gómez J, Baños V, Simarro E, Lorenzo Cruz M, Ruiz Gómez J, Latour J, Garcia Martin E, Canteras M, Valdes M (2000) Prospective, comparative study (1994-1998) of the influence of short-term prophylactic treatment with azithromycin on patients with advanced COPD. Rev Esp Quimioter 13:379-383 (Pubitemid 32125753)
113. Falagas ME, Avgeri SG, Matthaiou DK, Dimopoulos G, Siempos II (2008) Shortversus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J Antimicrob Chemother 62:442-450. doi:10.1093/jac/dkn201
114. Anzueto A, Rizzo JA, Grossman RF (1999) The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis. Clin Infect Dis 28:1344-1345. doi:10.1086/517802 (Pubitemid 29272832)
115. White AJ, Gompertz S, Bayley DL, Hill SL, O'Brien C, Unsal I, Stockley RA (2003) Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 58:680-685 (Pubitemid 36976277)
116. Llor C, Cots JM, Herreras A (2006) Bacterial etiology of chronic bronchitis exacerbations treated by primary care physicians. Arch Bronconeumol 42:388-393 (Pubitemid 44409170)
117. Dewan NA, Rafique S, Kanwar B, Satpathy H, Ryschon K, Tillotson GS, Niederman MS (2000) Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 117:662-761. doi:10.1378/chest.117.3.662
118. Patel IS, Seemungal TAR, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA (2002) Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 57:759-764 (Pubitemid 34984972)
119. Chodosh S, Schreurs A, Siami G, Barkman HW Jr, Anzueto A, Shan M, Moesker H, Stack T, Kowalsky S (1998) Efficacy of oral ciprofloxacin versus clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 27:730-738. doi:10.1086/514934 (Pubitemid 29244326)
120. Miravitlles M (2002) Exacerbations of chronic obstructive pulmonary disease: when are bacteria important. Eur Respir J 20:9s-19s (Pubitemid 34774184)
121. Sethi S, Evans N, Grant BJ, Murphy TF (2002) New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 347:465-471. doi:10.1056/NEJMoa012561 (Pubitemid 34879333)
122. Lode H, Eller J, Linnhoff A, Ioanas M, the Evaluation of Therapy-Free Interval in COPD Patients Study Group (2004) Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval. Eur Respir J 24:947-953. doi:10.1183/09031936.04.00009604 (Pubitemid 39642284)
123. Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK (2010) Comparative effectiveness of macrolides and quinolones for patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). J Hosp Med 5:261-267. doi:10.1002/jhm.628
124. Van Bambeke F, Tulkens PM (2009) Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 32:359-378. doi:10.2165/00002018-200932050-00001
125. Dvoretskiǐ LI, Dubrovskaia NV, Grudinina SA, Filimonova OIu, Sidorenko SV, Iakovlev SV (2007) Levofloxacin and macrolides in chronic bronchitis exacerbation: comparative analysis of the treatment efficacy and non relapsing periods. Antibiot Khimioter 52:21-31
126. Miravitlles M, Llor C, Naberan K, Cots JM, Molina J, for the EFEMAP study group (2005) Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Respir Med 99:955-965. doi:10.1016/j.rmed.2005.01.013 (Pubitemid 40796538)
127. Khan S, Javaid A, Ghori RA, Mahmood K, Anwer N, Khan SU, Iqbal ZH, Rahman F, Ullah S, Imran K, Akhter N, Khan MK, Siddqui SJ, Fareed A, Khan MH (2003) Cefaclor AF vs clarithromycin in acute exacerbation of chronic bronchitis (B3M-PK-AJBG). J Pak Med Assoc 53:338-345 (Pubitemid 37185735)
128. Weiss LR (2002) Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis. Clin Ther 24:1414-1425 (Pubitemid 35176973)
129. Alvarez Gutiérrez FJ, Soto Campos G, del Castillo OD, Sánchez Gómez J, Calderón Osuna E, Rodríguez Becerra E, Castillo Gómez J (1999) A randomized comparative study of 3 days of azithromycin treatment and 10 days of cefuroxime treatment in exacerbations in patients with chronic obstructive pulmonary disease. Med Clin (Barc) 113:124-128 (Pubitemid 29356590)
130. Andre-Alves MR, Jardim JR, Frare e Silva R, Fiss E, Freire DN, Teixeira PJ (2007) Comparison between azithromycin and amoxicillin in the treatment of infectious exacerbation of chronic obstructive pulmonary disease. J Bras Pneumol 33:43-50
131. Amsden GW, Baird IM, Simon S, Treadway G (2003) Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest 123:772-777 (Pubitemid 36315492)
132. Siempos II, Dimopoulos G, Korbila IP, Manta K, Falagas ME (2007) Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 29:1127-1137. doi:10.1183/09031936.00147806 (Pubitemid 46895371)
133. Wilson R, Schentag JJ, Ball P, Mandell L (2002) A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 24:639-652 (Pubitemid 34492885)
134. Wilson R, Allegra L, Huchon G, Izquierdo JL, Jones P, Schaberg T, Sagnier PP, MOSAIC Study Group (2004) Short and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 125:953-964 (Pubitemid 38367286)
135. Miravitlles M, Espinosa C, Ferna'ndez-Laso E, Martos JA, Maldonado JA, Gallego M (1999) Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 116:40-46 (Pubitemid 29340258)
136. Corne JM, Marshall C, Smith S, Schreiber J, Sanderson G, Holgate ST, Johnston SL (2002) Frequency, severity and duration of rhinovirus infections in asthmatics and non-asthmatic individuals: a longitudinal study. Lancet 359:831-834. doi:10.1016/S0140-6736(02)07953-9 (Pubitemid 34233753)
137. Papadopoulos NG, Papi A, Psarsas S, Johnston SL (2004) Mechanisms of rhinovirus induced asthma. Paediatr Respir Rev 5:255-260. doi:10.1016/j.prrv. 2004.04.002 (Pubitemid 39028850)
138. Haruna S, Shimada C, Ozawa M, Fukami S, Moriyama H (2009) A study of poor responders for long-term, low-dose macrolide administration for chronic sinusitis. Rhinology 47:66-71
139. Gielen V, Johnston SL, Edwards MR (2010) Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J 36:646-654. doi:10.1183/09031936.00095809
140. Korematsu S, Yamamoto K, Nagakura T, Miyahara H, Okazaki N, Akiyoshi K, Maeda T, Suenobu S, Izumi T (2000) The indication and effectiveness of low-dose erythromycin therapy in pediatric patients with bronchial asthma. Pediatr Allergy Immunol 21:489-492. doi:10.1111/j.1399-3038.2009.00941.x
141. Sato E, Nelson DK, Koyama S, Hoyt JC, Robbins RA (2001) Erythromycin modulates eosinophil chemotactic cytokine production by human lung fibroblasts in vitro. Antimicrob Agents Chemother 45:401-406. doi:10.1128/AAC.8.2.401-406. 2001 (Pubitemid 32105272)
142. Kaukoranta-Tolvanen SS, Teppo AM, Laitinen K, Saikku P, Limavuori K, Leinonen M (1966) Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and infection induction of cytokine response. Microb Pathog 21:215-221. doi:10.1006/mpat.1996.0056
143. Redecke V, Dalhoff K, Bohnet S, Braun J, Maas M (1998) Interaction of Chlamydia pneumoniae and human alveolar macrophages. Am J Respir Cell Mol Bio 19(5):721-7
144. Rottier BL, Duiverman EJ (2009) Anti-inflammatory drug therapy in asthma. Paediatr Respir Rev 10:214-219. doi:10.1016/j.prrv.2009.06.007
145. Feldman C, Anderson R, Theron AJ, Ramafi G, Cole PJ, Wilson R (1997) Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro. Inflammation 21:655-65 (Pubitemid 28026335)
146. Blasi F, Aliberti S, Allegra L, Piatti G, Tarsia P, Ossewaardl JM, Verweij V, Nijkamp FP, Folkerts G (2007) Chlamydia pneumoniae induces a sustained airway hyperresponsiveness and inflammation in mice. Respir Res 19:83. doi:10.1186/1465-9921-8-83
147. Rollins DR, Beuther DA, Martin RJ (2010) Update on infection and antibiotics in asthma. Curr Allergy Asthma Rep 10:67-73. doi:10.1007/s11882-009- 0086-2
148. Black PN (2007) Antibiotics for the treatment of asthma. Curr Opin Pharmacol 7:266-271. doi:10.1016/j.coph.2006.11.013 (Pubitemid 46744830)
149. Sharma S, Jaffe A, Dixon G (2007) Immunomodulatory effects of macrolide antibiotics in respiratory disease: therapeutic implications for asthma and cystic fibrosis. Paediatr Drugs 9:107-118 (Pubitemid 46624563)
150. Takizawa H (2007) Novel strategies for the treatment of asthma. Recent Pat Inflamm Allergy Drug Discov 1:13-19
151. Richeldi L, Ferrara G, Fabbri LM, Lasserson TJ, Gibson PG (2005) Macrolides for chronic asthma. Cochrane Database Syst Rev (4):CD002997. doi: 10.1002/14651858.CD002997.pub2
152. He JX, Zhao SY, Jiang ZF (2005) Demonstration of a mechanism of anti-inflammatory effect of erythromycin on allergic airway inflammation in rat. Zhonghua Er Ke Za Zhi 43:196-198
153. Blasi F, Cosentini R, Tarsia P, Allegra L (2004) Potential role of antibiotics in the treatment of asthma. Curr Drug Targets Inflamm Allergy 3:237-242 (Pubitemid 39206652)
154. Cazzola M, Matera MG, Blasi F (2004) Macrolide and occult infection in asthma. Curr Opin Pulm Med 10:7-14 (Pubitemid 38045895)
155. Piacentini GL, Peroni DG, Bodini A, Pigozzi R, Costella S, Loiacono A, Boner AL (2007) Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy Asthma Proc 28:194-198
156. Sutherland ER, King TS, Icitovic N, Ameredes BT, Bleecker E, Boushey HA, Calhoun WJ, Castro M, Cherniack RM, Chinchilli VM, Craig TJ, Denlinger L, DiMango EA, Fahy JV, Israel E, Jarjour N, Kraft M, Lazarus SC, Lemanske RF Jr, Peters SP, Ramsdell J, Sorkness CA, Szefler SJ, Walter MJ, Wasserman SI, Wechsler ME, Chu HW, Martin RJ, National Heart, Lung and Blood Institute's Asthma Clinical Research Network (2010) A trial of clarithromycin for the treatment of suboptimally controlled asthma. Allergy Clin Immunol 126:747-753. doi:10.1016/j.jaci.2010.07.024
157. Haruna S, Shimada C, Ozawa M, Fukami S, Moriyama H (2009) A study of poor responders for long-term, low-dose macrolide administration for chronic sinusitis. Rhinology 47:66-71
158. Ferrara G, Losi M, Franco F, Corbetta L, Fabbri LM, Richeldi L (2005) Macrolides in the treatment of asthma and cystic fibrosis. Respir Med 99:1-10 (Pubitemid 40017377)
159. Ogawa N, Sugawara Y, Fujiwara Y, Noma T (2003) Roxithromycin promotes lymphocyte apoptosis in Dermatophagoidessensitive asthma patients. Eur J Pharmacol 474:273-281 (Pubitemid 37281461)
160. Ekici A, Ekici M, Erdemoǧlu AK (2002) Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma. J Asthma 39:181-185. doi:10.1081/JAS-120002199 (Pubitemid 34464576)
161. Xiao W, Yu H, Zheng C (2000) The imbalance of Th1/Th2 cytokine expression in peripheral blood mononuclear cell from asthmatic patients and the effect of erythromycin on these cytokines. Zhonghua Jie He He Hu Xi Za Zhi 23:347-350
162. Spahn JD, Fost DA, Covar R, Martin RJ, Brown EE, Szefler SJ, Leung DY (2001) Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study. Ann Allergy Asthma Immunol 87:501-505 (Pubitemid 34001039)
163. Amayasu H, Yoshida S, Ebana S, Yamamoto Y, Nishikawa T, Shoji T, Nakagawa H, Hasegawa H, Nakabayashi M, Ishizaki Y (2000) Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 84:594-598 (Pubitemid 30418859)
164. Kostadima E, Tsiodras S, Alexopoulos EI, Kaditis AG, Mavrou I, Georgatou N, Papamichalopoulos A (2004) Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J 23:714-717. doi:10.1183/09031936.04.00118404 (Pubitemid 38618141)
165. Hatipoglu U, Rubinstein I (2004) Low-dose, long-term macro-lide therapy in asthma: an overview. Clin Mol Allergy 2:4. doi:10.1186/1476-7961-2-4 (Pubitemid 39111884)
166. Kutlin A, Roblin PM, Hammerschlag MR (2002) Effect of prolonged treatment with azithromycin, clarithromycin, or levo-floxacin on Chlamydia pneumoniae in a continuous-infection model. Antimicrob Agents Chemother 46:409-412. doi:10.1128/AAC.46.2.409-412.2002 (Pubitemid 34087188)
167. Black PN, Blasi F, Jenkins CR, Scicchitano R, Mills GD, Rubinfeld AR, Ruffin RE, Mullins PR, Dangain J, Cooper BC, David DB, Allegra L (2001) Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 164:536-541 (Pubitemid 32801652)
168. Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH (2000) Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest 118:1826-1827 (Pubitemid 32001818)
169. Gryglicka B, Wegrzyn-Szkutnik I, Michnar M, Mazur E, Niedźwiadek J, Milanowski J (2003) Evaluation of an anti-chlamydial antibiotic therapy influence on asthma patients. Ann Univ Mariae Curie Sklodowska Med 58:444-451
170. Shimizu T, Kato M, Mochizuki H, Takei K, Maeda S, Tokuyama K, Morikawa A (1997) Roxithromycin attenuates acid-induced cough and water-induced bronchoconstriction in children with asthma. J Asthma 34:211-217. doi:10.3109/02770909709068191 (Pubitemid 27270455)
171. Huang TJ, Eynott P, Salmon M, Nicklin PL, Chung KF (2002) Effect of topical immunomodulators on acute allergic inflammation and bronchial hyperresponsiveness in sensitised rats. Eur J Pharmacol 437:187-194 (Pubitemid 34219481)
172. Shoji T, Yoshida S, Sakamoto H, Hasegawa H, Nakagawa H, Amayasu H (1999) Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clin Exp Allergy 29:950-956. doi:10.1046/j.1365-2222.1999.00551.x (Pubitemid 29317806)
173. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG (2008) Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 177:148-155. doi:10.1164/rccm.200707-1134OC
174. Chu HW, Kraft M, Rex MD, Martin RJ (2001) Evaluation of blood vessels and edema in the airways of asthma patients: regulation with clarithromycin treatment. Chest 120:416-422 (Pubitemid 32881256)
175. Nelson HS, Hamilos DL, Corsello PR, Levesque NV, Buchmeier AD, Bucher BL (1993) A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. Am Rev Respir Dis 147(2):398-404 (Pubitemid 23044914)
176. Kamada AK, Hill MR, Iklé DN, Brenner AM, Szefler SJ (1993) Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. J Allergy Clin Immunol 91(4):873-882. doi:10.1016/0091-6749(93)90345-G (Pubitemid 23118504)
177. Johnston SL, Blasi F, Black PN, Martin RJ, Farrell DJ, Nieman RB, Investigators TELICAST (2006) The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 354(15):1589-1600. doi:10.1056/NEJMoa044080
178. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J (2005) ATS/ERS Task Force: standardisation of spirometry. Eur Respir J 26 (2):319-338. doi:10.1183/09031936.00130010 (Pubitemid 41079078)
179. Miyatake H, Taki F, Taniguchi H, Suzuki R, Takagi K, Satake T, Miyatake H, Taki F, Taniguchi H, Suzuki R, Takagi K, Satake T (1991) Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest 99(3):670-673. doi:10.1378/chest.99.3.670
180. Hersperger R, Buchheit KH, Cammisuli S, Enz A, Lohse O, Ponelle M, Schuler W, Schweitzer A, Walker C, Zehender H, Zenke G, Zimmerlin AG, Zollinger M, Mazzoni L, Fozard JR (2004) A locally active antiinflammatory macrolide (MLD987) for inhalation therapy of asthma. J Med Chem 47:4950-4957. doi:10.1021/jm031101l (Pubitemid 39238270)
181. Govan JR, Nelson JW (1992) Microbiology of lung infection in cystic fibrosis. Br Med Bull 48:912-930
182. Kahn TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW (1995) Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151:1075-1082
183. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Gutièrrez JP, Hull J, Olinsky A, Phelan EM, Robertson CF, Phelan PD (1997) Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 156:1197-1204
184. Ramsey B (1996) Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 335:179-188. doi:10.1056/NEJM199607183350307 (Pubitemid 26249456)
185. Armstrong DS, Grimwood K, Carzino R, Gutièrrez JP, Hull J, Olinsky A, Phelan EM, Robertson CF, Phelan PD (1995) Lower respiratory tract infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 310:1571-1572
186. Konstan MW, Hilliard KA, Norvell TM, Berger M (1994) Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 150:448-454 (Pubitemid 24252357)
187. Auerbach HS, William M, Kirkpatrick JA, Cloten HR (1985) Alternate day prednisolone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 2:686-688. doi:10.1016/S0140-6736(85)92929-0 (Pubitemid 15244944)
188. Eigen H, Rosenstein BJ, Fitzsimmons S, Schidlow DV, Cystic Fibrosis Foundation Prednisolone Trial Group (1995) A multicenter study of alternate day prednisolone therapy in patients with cystic fibrosis. J Pediatr 126:515-523. doi:10.1016/S0022-3476(95)70343-8
189. Jaffe A, Bush A (2001) Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 31:464-473. doi:10.1002/ppul.1076 (Pubitemid 32523640)
190. Tai S, Sudo E, Sun F et al (1999) Effect of azithromycin on sputum rheology in cystic fibrosis patients (abstract). Pediatr Pulmonol Suppl 19:264
191. Fisher JJ, Baumon U, Gudowius P et al (1999) Azithromycin reduces epithelial adherence of P. aeruginosa in patients with cystic fibrosis (abstract). Pediatr Pulmonol Suppl 19:265
192. Fecik RA, Nguyen PL, Venkatraman L (2005) Approaches to the synthesis of immunolides: selective immunomodulatory macrolides for cystic fibrosis. Curr Opin Drug Discov Devel 8:741-747 (Pubitemid 41659402)
193. Bell SC, Senini SL, McCormack JG (2005) Macrolides in cystic fibrosis. Chron Respir Dis 2:85-98. doi:10.1191/1479972305cd066rs (Pubitemid 40546607)
194. Equi AC, Davies JC, Painter H, Hyde S, Bush A, Geddes DM, Alton EW (2006) Exploring the mechanisms of macrolides in cystic fibrosis. Respir Med 100:687-697. doi:10.1016/j. rmed.2005.07.016 (Pubitemid 43285757)
195. Cai Y, Chai D, Wang R, Bai N, Liang BB, Liu Y (2011) Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. J Antimicrob Chemother 66:968-978. doi:10.1093/jac/dkr040
196. Yousef AA, Jaffe A (2010) The role of azithromycin in patients with cystic fibrosis. Paediatr Respir Rev: 108-114. doi: 10.1016/j.prrv.2009.12.003
197. Doǧru D, Dalgiç F, Kiper N, Ozçelik U, Yalçin E, Aslan AT, Gürcan N, Saricaoǧlu F, Gür D, Karayazgan Y, Firat P (2009) Long-term clarithromycin in cystic fibrosis: effects on inflammatory markers in BAL and clinical status. Turk J Pediatr 51:416-423
198. Kabra SK, Pawaiya R, Lodha R, Kapil A, Kabra M, Vani AS, Agarwal G, Shastri SS (2010) Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. J Cyst Fibros 9:17-23. doi:10.1016/j.jcf.2009.09.001
199. Oliynyk I, Varelogianni G, Schalling M, Asplund MS, Roomans GM, Johannesson M (2009) Azithromycin increases chloride efflux from cystic fibrosis airway epithelial cells. Exp Lung Res 35:210-221. doi:10.1080/01902140802534967
200. Florescu DF, Murphy PJ, Kalil AC (2009) Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis. Pulm Pharmacol Ther 22:467-472. doi:10.1016/j. pupt.2009.03.002
201. Tsai WC, Hershenson MB, Zhou Y, Sajjan U (2009) Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice. Inflamm Res 58:491-501. doi:10.1007/s00011-009-0015-9
202. Hansen CR, Pressler T, Hoiby N, Johansen HK (2009) Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients. J Cyst Fibros 8:58-62. doi:10.1016/j. jcf.2008.09.001
203. Steinkamp G, Schmitt-Grohe S, Döring G, Staab D, Pfründer D, Beck G, Schubert R, Zielen S (2008) Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respir Med 102:164316-53
204. Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P (2007) Effects of azithromycin on the expression of ATP binding cassette transporters in epithelial cells from the airways of cystic fibrosis patients. J Chemother 19:643-649. doi:10.1016/j. rmed.2008.03.009 (Pubitemid 351212011)
205. Nguyen D, Emond MJ, Mayer-Hamblett N, Saiman L, Marshall BC, Burns JL (2007) Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatr Pulmonol 42:533-541. doi:10.1002/ppul.20620 (Pubitemid 46870385)
206. McArdle JR, Talwalkar JS (2007) Macrolides in cystic fibrosis. Clin Chest Med 28(2):347-360 (Pubitemid 46654478)
207. Fayon M, Airway-Inflammation Group, Société Française de Mucoviscidose (2006) CF-Emerging therapies: modulation inflammation. Paediatr Respir Rev7 Suppl 1:S170-S174. doi: 10.1016/j.prrv.2006. 04.212 (Pubitemid 43958382)
208. Wilms EB, Touw DJ, Heijerman HG (2006) Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis. Ther Drug Monit 28:219-225. doi:10.1097/01. ftd.0000195617.69721.a5 (Pubitemid 44270929)
209. Prescott WA Jr, Johnson CE (2005) Antiinflammatory therapies for cystic fibrosis: past, present, and future. Pharmacotherapy 25:555-573 (Pubitemid 40471498)
210. Hansen CR, Pressler T, Koch C, Høiby N (2005) Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros 4:35-40. doi:10.1016/j.jcf.2004.09.001 (Pubitemid 40347775)
211. Saiman L (2004) The use of macrolide antibiotics in patients with cystic fibrosis. Curr Opin Pulm Med 10:515-523 (Pubitemid 39441447)
212. Pirzada OM, McGaw J, Taylor CJ, Everard ML (2003) Improved lung function and body mass index associated with long-term use of macrolide antibiotics. J Cyst Fibros 2:69-71. doi:10.1016/S1569-1993(03)00021-3 (Pubitemid 36814092)
213. Carr RR, Nahata MC (2004) Azithromycin for improving pulmonary function in cystic fibrosis. Ann Pharmacother 38:1520-1524. doi:10.1345/aph.1D589 (Pubitemid 39100209)
214. Southern KW, Barker PM, Solis A (2004) Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev (2):CD002203. doi: 10.1002/14651858. CD002203.pub2
215. Wolter JM, Seeney SL, McCormack JG (2002) Macrolides in cystic fibrosis: is there a role? Am J Respir Med 1:235-241 (Pubitemid 37038942)
216. Gaylor AS, Reilly JC (2002) Therapy with macrolides in patients with cystic fibrosis. Pharmacotherapy 22:227-239 (Pubitemid 34112883)
217. Oermann CM (2001) Anti-inflammatory approaches to the treatment of cystic fibrosis lung disease: past, present and future. Curr Opin Investig Drugs 2:90090-6
218. Pukhalsky AL, Shmarina GV, Kapranov NI, Kokarovtseva SN, Pukhalskaya D, Kashirskaja NJ (2004) Anti-inflammatory and immune-modulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediators Inflamm 13:111-117. doi:10.1080/09629350410001688495 (Pubitemid 38698140)
219. Wagner T, Soong G, Sokol S, Saiman L, Prince A (2005) Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients. Chest 128:912-919. doi:10.1378/chest.128.2.912 (Pubitemid 41140526)
220. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J (2002) Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 57:21221-6
221. Beringer P, Huynh KM, Kriengkauykiat J, Bi L, Hoem N, Louie S, Han E, Nguyen T, Hsu D, Rao PA, Shapiro B, Gill M (2005) Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. Antimicrob Agents Chemother 49:5013-5017. doi:10.1128/AAC.49.12.5013-5017.2005 (Pubitemid 41778914)
222. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW 3rd, Macrolide Study Group (2003) Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290:1749-1756. doi:10.1001/jama.290.13.1749 (Pubitemid 37430625)
223. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP (2006) Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 61:895-902 (Pubitemid 44570311)
224. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Burns JL, Marshall BC, Ratjen F, AZ0004 Azithromycin Study Group (2010) Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 303:1707-1715. doi:10.1001/jama.2010.563
225. McCormack J, Bell S, Senini S, Walmsley K, Patel K, Wainwright C, Serisier D, Harris M, Bowler S (2007) Daily versus weekly azithromycin in cystic fibrosis patients. Eur Respir J 30:487-495. doi:10.1183/09031936.00163306 (Pubitemid 351182072)
226. Baumann U, King M, App EM, Tai S, König A, Fischer JJ, Zimmermann T, Sextro W, von der Hardt H (2004) Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties. Can Respir J 11:151-155 (Pubitemid 38519175)
227. Saiman L, Mayer-Hamblett N, Campbell P, Marshall BC, Macrolide Study Group (2005) Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 172:1008-1012. doi: 10.1164/rccm.200502-218OC (Pubitemid 41476538)
228. Oliynyk I, Varelogianni G, Schalling M, Asplund MS, Roomans GM, Johannesson M (2009) Azithromycin increases chloride efflux from cystic fibrosis airway epithelial cells. Exp Lung Res 35:210-221. doi:10.1080/01902140802534967
229. Gavilanes X, Huaux F, Meyer M, Lebecque P, Marbaix E, Lison D, Scholte B, Wallemacq P, Leal T (2009) Azithromycin fails to reduce increased expression of neutrophil-related cytokines in primary-cultured epithelial cells from cystic fibrosis mice. J Cyst Fibros 8:203-210. doi:10.1016/j.jcf.2009.03.003
230. Meyer M, Hodson M, Bush A (2007) Respiratory disease: non-infectious complications. In: Hodson M, Geddes D, Bush A (eds) Cystic fibrosis, 3rd ed. Arnold, London, p. 166-167
231. Floto RA, Haworth (2011) Bronchiectasis. European respiratory monograph 52. European Respiratory Society, Sheffield
232. Wilson R (2002) Bronchiectasis. In: Gibson J, Geddes D, Costabel U (eds) Respiratory medicine, 3rd ed. WB Saunders, Edinburgh, pp 1145-464
233. Rayner CF, Tillotson G, Cole PJ, Wilson R (1994) Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis. J Antimicrob Chemother 34:149-156. doi:10.1093/jac/34.1.149 (Pubitemid 24237603)
234. Serisier DJ, Martin ML (2011) Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respir Med 105:946-949. doi:10.1016/j.rmed.2011.01.009
235. Anwar GA, Bourke SC, Afolabi G, Middleton P, Ward C, Rutherford RM (2008) Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med 102:1494-1496. doi:10.1016/j.rmed.2008.06.005
236. Verleden GM, Dupont LJ, Vanhaecke J, Daenen W, Van Raemdonck DE (2005) Effect of azithromycin on bronchiectasis and pulmonary function in a heart-lung transplant patient with severe chronic allograft dysfunction: a case report. J Heart Lung Transplant 24:1155-1158. doi:10.1016/j.healun.2004.06.025 (Pubitemid 41127211)
237. Cymbala AA, Edmonds LC, Bauer MA, Jederlinic PJ, May JJ, Victory JM, Amsden GW (2005) The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 4:117-122 (Pubitemid 40613959)
238. Shibuya Y, Wills PJ, Cole PJ (2002) The effect of erythromycin on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum. Respiration 68:615-619
239. Tsang KW, Roberts P, Read RC, Kees F, Wilson R, Cole PJ (1994) The concentrations of clarithromycin and its 14-hydroxy metabolite in sputum of patients with bronchiectasis following single dose oral administration. J Antimicrob Chemother 33:289-297. doi:10.1093/jac/33.2.289 (Pubitemid 24076808)
240. Tsang KW, Ho PI, Chan KN, Ip MS, Lam WK, Ho CS, Yuen KY, Ooi GC, Amitani R, Tanaka E (1999) A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 13:361-364 (Pubitemid 29086834)
241. Crosbie PA, Woodhead MA (2009) Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 33:171-181. doi:10.1183/09031936. 00042208
242. Yalcin E, KiperN OU, Doǧru D, Firat P, Sahin A, Ariyürek M, Mocan G, Gürcan N, Göçmen A (2006) Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther 31:49-55. doi:10.1111/j.1365-2710.2006.00708.x
243. Davies G, Wilson R (2004) Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax 59(6):540-541 (Pubitemid 38797534)
244. Koh YY, Lee MH, Sun YH, Sung KW, Chae JH (1997) Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 10(5):994-999 (Pubitemid 27201800)
245. Dhillon GS, Valentine VG, Levitt J, Patel P, Gupta MR, Duncan SR, Seoane L, Weill D (2011) Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft recipients. Clin Transplant 24. doi:10.1111/j.1399- 0012.2011.01420.x
246. Remund K, Rechsteiner T, Guo Z, Rentsch K, Boehler A (2009) The macrolide clarithromycin inhibits experimental post-transplant bronchiolitis obliterans. Exp Lung Res 35:830-840. doi:10.3109/01902140902918755
247. Keicho N, Kudoh S (2002) Diffuse panbronchiolitis: role of macrolides in therapy. Am J Respir Med 1:119-131 (Pubitemid 37038930)
248. Fietta AM, Meloni F (2008) Lung transplantation: the role of azithromycin in the management of patients with bronchiolitis obliterans syndrome. Curr Med Chem 15:716-723 (Pubitemid 351516807)
249. Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T (2008) Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 85:36-41. doi:10.1097/01.tp.0000295981.84633.bc
250. Shitrit D, Bendayan D, Gidon S, Saute M, Bakal I, Kramer MR (2005) Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 24:1440-1443 (Pubitemid 41247833)
251. Kadota J, Mukae H, Tomono K, Kohno S, Nasu M (2004) Efficacy of long-term macrolide antibiotic therapy in patients with diffuse panbronchiolitis: comparison between HLA-B54-positive and -negative cases. Int J Antimicrob Agents 24:550-554. doi:10.1016/j.ijantimicag.2004.07.012 (Pubitemid 39536108)
252. Park SJ, Lee YC, Rhee YK, Lee HB (2004) The effect of long-term treatment with erythromycin on Th1 and Th2 cytokines in diffuse panbronchiolitis. Biochem Biophys Res Commun 324:114-117
253. Verleden GM, Dupont LJ (2004) Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 77:1465-1467 (Pubitemid 38668447)
254. Kadota J, Mukae H, Ishii H, Nagata T, Kaida H, Tomono K, Kohno S (2003) Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med 97:8448-50
255. Liu Y, Hu H, Zhang J (1999) A clinical trial of 14 and 15 membered macrolides in treating six cases of diffuse panbronchiolitis. Zhonghua Nei Ke Za Zhi 38:622-624
256. Jain R, Hachem RR, Morrell MR, Trulock EP, Chakinala MM, Yusen RD, Huang HJ, Mohanakumar T, Patterson GA, Walter MJ (2010) Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant 29:531-537. doi:10.1016/j.healun. 2009.12.003
257. Porhownik NR, Batobara W, Kepron W, Unruh HW, Bshouty Z (2008) Effect of maintenance azithromycin on established bronchiolitis obliterans syndrome in lung transplant patients. Can Respir J 15:199-202
258. Yates B, Murphy DM, Forrest IA, Ward C, Rutherford RM, Fisher AJ, Lordan JL, Dark JH, Corris PA (2005) Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 172:772-775. doi:10.1164/rccm.200411-1537OC (Pubitemid 41324235)
259. Vanaudenaerde BM, Meyts I, Vos R, Geudens N, De Wever W, Verbeken EK, Van Raemdonck DE, Dupont LJ, Verleden GM (2008) A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 32:832-843. doi:10.1183/09031936.00134307
260. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE (2006) Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 174:566-570. doi:10.1164/rccm.200601-071OC (Pubitemid 44330550)
261. Kaneko Y, Yanagihara K, Seki M, Kuroki M, Miyazaki Y, Hirakata Y, Mukae H, Tomono K, Kadota J, Kohno S (2003) Clarithromycin inhibits overproduction of muc5ac core protein in murine model of diffuse panbronchiolitis. Am J Physiol Lung Cell Mol Physiol 285: L847-853. doi:10.1152/ajplung.00216.2002 (Pubitemid 37158831)
262. Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB (2003) Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 168:121-125. doi:10.1164/rccm. 200212-1424BC (Pubitemid 37046642)
263. Sugiyama Y, Kudoh S, Maeda H (1990) Analysis of HLA antigens in patients with diffuse panbronchiolitis. Am Rev Respir Dis 141:1459-1462 (Pubitemid 20201342)
264. Nagai H, Shishido H, Yoneda R (1991) Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 58:145-149
265. Khalid M, Al Saghir A, Saleemi S, Al Dammas S, Zeitouni M, Al Mobeireek A, Chaudhry N, Sahovic E (2005) Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J 25:490-493. doi:10.1183/09031936.05.00020804 (Pubitemid 40340107)
266. Vos R, Vanaudenaerde BM, Ottevaere A, Verleden SE, De Vleeschauwer SI, Willems-Widyastuti A, Wauters S, Van Raemdonck DE, Nawrot TS, Dupont LJ, Verleden GM (2010) Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer? Heart Lung Transplant 29:1358-1368. doi:10.1016/j.healun.2010.05.023
267. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M (1998) Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 157(6 Pt 1):1829-1832
268. Belser JA, Zeng H, Katz JM, Tumpey TM (2011) Infection with highly pathogenic H7 influenza viruses results in an attenuated proinflammatory cytokine and chemokine response early after infection. J Infect Dis 203:40-48. doi:10.1093/infdis/jiq018
269. Maines TR, Szretter KJ, Perrone L, Belser JA, Bright RA, Zeng H, Tumpey TM, Katz JM (2008) Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune response. Immunol Rev 225:68-84. doi:10.1111/j.1600- 065X.2008.00690.x
270. Us D (2008) Cytokine storm in avian influenza. Mikrobiyol Bul 42:365-380
271. Woo PC, Tung ET, Chan KH, Lau CC, Lau SK, Yuen KY (2010) Cytokine profiles induced by the novel swine-origin influenza A/H1N1 virus: implications for treatment strategies. J Infect Dis 201:346-353. doi:10.1086/649785
272. Lee SM, Gardy JL, Cheung CY, Cheung TK, Hui KP, Ip NY, Guan Y, Hancock RE, Peiris JS (2009) Systems-level comparison of host-responses elicited by avian H5N1 and seasonal H1N1 influenza viruses in primary human macrophages. PLoS One 4 (12):e8072. doi:10.1371/journal.pone.0008072
273. Zhang C, Xu Y, Jia L, Yang Y, Wang Y, Sun Y, Huang L, Qiao F, Tomlinson S, Liu X, Zhou Y, Song H (2010) A new therapeutic strategy for lung tissue injury induced by influenza with CR2 targeting complement inhibitor. Virol J 7:30. doi:10.1186/1743-422X-7-30
274. Shishkina LN, Nebol'sin VE, Skarnovich MO, Kabanov AS, Sergeev AA, Erdyneeva UB, Serova OA, Demina OK, Agafonov AP, Stavskiǐ EA, Drozdov IG (2010) In vivo efficacy of Ingavirin against pandemic A (H1N1/09)v influenza virus. Antibiot Khimioter 55:32-35
275. Bermejo-Martin JF, Kelvin DJ, Eiros JM, Castrodeza J, Ortiz de Lejarazu R (2009) Macrolides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strains. J Infect Dev Ctries 3(3):159-161
276. Miyamoto D, Hasegawa S, Sriwilaijaroen N, Yingsakmongkon S, Hiramatsu H, Takahashi T, Hidari K, Guo CT, Sakano Y, Suzuki T, Suzuki Y (2008) Clarithromycin inhibits progeny virus production from human influenza virus-infected host cells. Biol Pharm Bull 31(2):217-222 (Pubitemid 351198393)
277. Zhirnov O, Klenk HD (2003) Human influenza A viruses are proteolytically activated and do not induce apoptosis in CACO-2 cells. Virology 313(1):198-212 (Pubitemid 37013604)
278. Targowski T, Jahnz-Rózyk K (2010) The role of macrolides in treatment of exacerbations of chronic obstructive pulmonary disease. Pol Merkur Lekarski 28(166):311-314
279. De Souza-Galvao ML, Martínez-García MA, Sanz F, Blanquer J (2010) Hot topics respiratory infections. Arch Bronconeumo l46 Suppl 1:8-12. doi: 10.1016/S0300-2896(10)70003-X
280. Burgel PR (2006) Antibiotics for acute exacerbations of chronic obstructive pulmonary disease (COPD). Med Mal Infect 36:706-717. doi:10.1016/j.medmal.2006.05.011 (Pubitemid 44873175)
281. Beigelman A, Mikols CL, Gunsten SP, Cannon CL, Brody SL, Walter MJ (2010) Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis. Respir Res 11:90. doi:10.1186/1465-9921-11-90
282. Tahan F, Ozcan A, Koc N (2007) Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial. Eur Respir J 29:91-97. doi:10.1183/09031936.00029206 (Pubitemid 46092003)
283. Viasus D, Paño-Pardo JR, Cordero E, Campins A, López-Medrano F, Villoslada A, Fariñas MC, Moreno A, Rodríguez-Baño J, Oteo JA, Martínez-Montauti J, Torre-Cisneros J, Segura F, Carratalà J, Novel Influenza A (H1N1) Study Group, Spanish Network for Research in Infectious Diseases (2011) Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J Infect 62:193-199. doi:10.1016/j.jinf.2011.01.014
284. Ichikawa Y, Ninomiya H, Katsuki M, Hotta M, Tanaka M, Oizumi K (1993) Low-dose/long-term erythromycin for treatment of bronchiolitis obliterans organizing pneumonia (BOOP). Kurume Med J 40:65-67 (Pubitemid 23323135)
285. Stover DE, Mangino D (2005) Macrolides: a treatment alternative for bronchiolitis obliterans organizing pneumonia. Chest 128:3611-3617. doi:10.1378/chest.128.5.3611 (Pubitemid 41698700)
286. Radzikowska E, Wiatr E, Gawryluk D, Langfort R, Bestry I, Chabowski M, Roszkowski K (2008) Organizing pneumonia-clarithromycin treatment. Pneumonol Alergol Pol 76:334-339
287. Chang J, Han J, Kim D, Lee I, Lee KY, Jung S, Han HS, Chun BK, Cho SJ, Lee K, Lim BJ, Shin DH (2002) Bronchiolitis obliterans organizing pneumonia: clinicopathologic review of a series of 45 Korean patients including rapidly progressive form. J Korean Med Sci 17:179-186
288. Purcell IF, Bourke SJ, Marshall SM (1997) Cyclophosphamide in severe steroid-resistant bronchiolitis obliterans organizing pneumonia. Respir Med 91:175-177 (Pubitemid 27122669)
289. Koinuma D, Miki M, Ebina M, Tahara M, Hagiwara K, Kondo T, Taguchi Y, Nukiwa T (2002) Successful treatment of a case with rapidly progressive bronchiolitis obliterans organizing pneumonia (BOOP) using cyclosporin A and corticosteroid. Intern Med 41:26-29 (Pubitemid 34196205)
290. Kobayashi I, Yamada M, Takahashi Y, Kawamura N, Okano M, Sakiyama Y, Kobayashi K (2003) Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A. Rheumatology 42:371-374. doi:10.1093/rheumatology/keg040 (Pubitemid 36305628)
291. Radzikowska E, Wiatr E, Langfort R, Bestry I, Rudziński P, Roszkowski K (2004) Organizing pneumonia - own experiences with clarithromycin treatment. Pneumonol Alergol Pol 72:493-498 (Pubitemid 41072956)
292. Lee J, Cha SI, Park TI, Park JY, Jung TH, Kim CH (2011) Adjunctive effects of cyclosporine and macrolide in rapidly progressive cryptogenic organizing pneumonia with no prompt response to steroid. Intern Med 50:475-479
293. King TE Jr, Mortenson RL (1992) Cryptogenic organizing pneumonitis. The North American experience. Chest 102:8S-13S. doi:10.1378/chest.102.1-Supplement. 8S
294. Periti P, Mazzei T, Mini E (2003) Adverse effects of macrolide antibacterials. Drug Saf 9:346-364
295. Brown BA, Griffith DE, Girard W, Levin J, Wallace RJ Jr (1997) Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. Clin Infect Dis 24(5):958-964. doi:10.2307/4459965 (Pubitemid 27193885)
296. Brummett RE, Fox KE (1989) Vancomycin- and erythromycin-induced hearing loss in humans. Antimicrob Agents Chemother 33(6):791-796 (Pubitemid 19146560)
297. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT, Onyi GO, Steingrube VA, Mazurek GH (1994) Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med 149 (5):1335-1341 (Pubitemid 24147078)
298. Wallace RJ Jr, Brown BA, Griffith DE (1993) Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis 16(3):215-221 (Pubitemid 23107304)
299. Foulds G, Shepard RM, Johnson RB (1990) The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 25 Suppl A:73-82 (Pubitemid 20043952)
300. Schentag JJ, Ballow CH (1991) Tissue-directed pharmacokinetics. Am J Med 91(3A):5S-11S
301. Luke DR, Foulds G, Cuddigan M, et al (1995) Azithromycin safety, toleration, and pharmacokinetics after intravenous administration [abstract no A27]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). American Society for Microbiology, Washington, DC
302. Brown BA, Wallace RJ Jr, Griffith DE, Girard W (1995) Clarithromycin-induced hepatoxicity [letter]. Clin Infect Dis 20:1073-1074
303. Volberg WA, Koci BJ, Su W (2002) Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther 302:320-327 (Pubitemid 34680454)
304. Dautzenberg B, Saint Marc T, Meyohas MC, Eliaszewitch M, Haniez F, Rogues AM, De Wit S, Cotte L, Chauvin JP, Grosset J (1993) Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch Intern Med 153(3):368-372 (Pubitemid 23058981)
305. Chaisson RE, Benson C, Dube M, Korvick J, Wu A, Lichter S, Dellerson M, Smith T, Sattler F (1992) Clarithromycin therapy for disseminated Mycobacterium avium-complex (MAC) in AIDS (abstract). The 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Annual Meeting of the American Society for Microbiology, Anaheim, CA
306. Sacristán JA, Soto JA, de Cos MA (1993) Erythromycin-induced hypoacusis: 11 new cases and literature review. Ann Pharmacother 27(7-8):950-955 (Pubitemid 23225689)
307. Haydon RC, Thelin JW, Davis WE (1984) Erythromycin ototoxicity: analysis and conclusions based on 22 case reports. Otolaryngol Head Neck Surg 92(6):678-684 (Pubitemid 15124101)
308. Principi N, Esposito S (1999) Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. Drug Saf 20:25-41 (Pubitemid 29041613)
309. Wallace MR, Miller LK, Nguyen MT (1994) Ototoxicity with azithromycin. Lancet 343:241
310. Ray WA, Murray KT, Meredith S (2004) Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 351:1089-1096. doi:10.1056/NEJMoa040582 (Pubitemid 39167513)
311. Owens RC Jr, Nolin TD (2006) Antimicrobial-associated QT interval prolongation: points of interest. Clin Infect Dis 43:1603-1611. doi:10.1086/508873 (Pubitemid 44910994)
312. Paran Y, Mashav N, Henis O (2008) Drug-induced torsades de pointes in patients aged 80 years or more. Anadolu Kardiyol Derg 8:260-265
313. Shaffer D, Singer S, Korvick J (2002) Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis 35:197-200. doi:10.2307/4462038 (Pubitemid 34753906)
314. Eady EA, Ross JI, Cove JH, Holland KT, Cunliffe WJ (1989) Macrolide-lincosamide-streptogramin B (MLS) resistance in cutaneous propionibacteria: definition of phenotypes. J Antimicrob Chemother 23(4):493-502. doi:10.1093/jac/23.4.493 (Pubitemid 19119060)
315. Bejuk D (2004) Differentiation of resistance phenotypes among erythromycin-resistant streptococci. Acta Med Croatica 58 (4):301-306 (Pubitemid 40137525)
316. Tunçkanat F, Arikan S (2000) Phenotypes of staphylococcal resistance to macrolides, lincosamides and streptogramin B (MLS) in a Turkish university hospital. Zentralbl Bakteriol 289 (8):827-833. doi:10.1016/S1684- 1182(10)60081-3 (Pubitemid 30097544)
317. Portillo A, Lantero M, Olarte I, Ruiz-Larrea F, Torres C (2001) MLS resistance phenotypes and mechanisms in beta-haemolytic group B, C and G Streptococcus isolates in La Rioja, Spain. J Antimicrob Chemother 47(1):115-116. doi:10.1093/jac/47.1.115 (Pubitemid 32058767)
318. Berg HF, Tjhie JH, Scheffer GJ, Peeters MF, van Keulen PH, Kluytmans JA, Stobberingh EE (2004) Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, doubleblind, placebo-controlled study. Antimicrob Agents Chemother 48(11):4183-4188. doi:10.1128/AAC.48.11.4183-4188.2004 (Pubitemid 39434873)
319. Tateda K, Ishii Y, Kimura S (2007) Suppression of Pseudomonas aeruginosa quorum-sensing systems by macrolides: a promising strategy or an oriental mystery? J Infect Chemother 13:357-367. doi:10.1007/s10156-007-0555-2 (Pubitemid 350308158)
320. Cazalis J, Tanabe S, Gagnon G, Sorsa T, Grenier D (2009) Tetracyclines and chemically modified tetracycline-3 (CMT-3) modulate cytokine secretion by lipopolysaccharide-stimulated whole blood. Inflammation 32(2):130-137. doi:10.1007/s10753-009-9111-9
321. Golub LM, Suomalainen K, Sorsa T (1992) Host modulation with tetracyclines and their chemically modified analogues. Curr Opin Dent 2:80-90
322. Maisi P, Kiili M, Raulo SM, Pirilä E, Sorsa T (1999) MMP inhibition by chemically modified tetracycline-3 (CMT-3) in equine pulmonary epithelial lining fluid. Ann N Y Acad Sci 878:675-677. doi:10.1111/j.1749-6632.1999. tb07759.x (Pubitemid 29353645)
323. Maitra SR, Bhaduri S, Chen E, Shapiro MJ (2004) Role of chemically modified tetracycline on TNF-alpha and mitogen-activated protein kinases in sepsis. Shock 22(5):478-481 (Pubitemid 39472574)
324. Steinberg J, Halter J, Schiller H, Gatto L, Carney D, Lee HM, Golub L, Nieman G (2005) Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model. Shock 24(4):348-356 (Pubitemid 41416521)
325. Reisz G, Pingleton SK, Melethil S, Ryan PB (1983) The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis. Am Rev Respir Dis 127:581-584 (Pubitemid 13087066)
326. Bachmann K, Jauregui L, Sides G, Sullivan TJ (1993) Steady-state pharmacokinetics of theophylline in COPD patients treated with dirithromycin. J Clin Pharmacol 33:861-865 (Pubitemid 23289680)
327. Cazzola M, Matera MG, Paternò E, Scaglione F, Santangelo G, Rossi F (1991) Impact of rokitamycin, a new 16-membered macrolide, on serum theophylline. J Chemother 3:240-244
328. Green JA, Clementi WA (1983) Decrease in theophylline clearance after the administration of erythromycin to a patient with obstructive lung disease. Drug Intell Clin Pharm 17:370-372 (Pubitemid 13079723)